Biohacking & Life Tracking

D&I webinar series

Webinar
tiistai 23.11.2021
klo 9.00 – 10.00
Tiedustelut:
[email protected]

D&I Innovation Powerhouse webinar:

Biohacking & Life Tracking – miten terveystiedoista luodaan vastuullista liiketoimintaa

D&I Innovation Powerhousen  webinaarisarjan syksyn viimeisessä osassa tarkastelemme, miten kuluttajan itsestään keräämistä tiedoista, erityisesti terveystiedoista, luodaan vastuullista liiketoimintaa.

Webinaarissa Juli Mansnérus, Iiris Kivikari ja Mirva Arvola kertovat, minkälaista juridiikkaa biohakkerointi ja kehonmittaus kätkevät sisäänsä ja mitä yritysten tulisi ottaa huomioon hyödyntäessään tällaista tietoa esimerkiksi tuotekehityksessään, kuluttajapalveluiden tarjoamisessa taikka tieteellisessä tutkimuksessa.

Pureudumme myös yrityskaupan jälkeiseen tiedon uudelleen järjestelyyn ja terveysdatan käytön kilpailuoikeudellisiin puoliin muun muassa Euroopan komission Google/Fitbit-tapauksen kautta.

Jos et ole saanut kutsua tilaisuuteen ja haluaisit osallistua, voit olla yhteydessä:
[email protected]
Tilaisuutemme ovat ensisijaisesti tarkoitettu asiakkaillemme ja muille sidosryhmillemme.

 

In D&I Innovation Powerhouse’s webinar series our lawyers address topical issues such as cooperation with authorities, legislation of AI-technologies and development, regulation, data transfers and reporting to the company executives.

More by the same author

The European pharmaceuticals legislation in transition – Finnish perspectives

As part of the EU’s aim to create a stronger European Health Union, the European Commission (“Commission”) published a Pharmaceutical Strategy for the EU (“Strategy”) in November 2020. More recently, the COVID-19 pandemic has highlighted several shortcomings in the EU’s current pharmaceutical system and showed the vulnerability of global supply chains. The Commission now plans to review and revise the EU’s general legislation on medicines for human use to ensure “a future-proof and crisis-resistant medicines regulatory system”. Simultaneously, the Member States of the EU, such as Finland, are dealing with some severe challenges with the economic sustainability of their healthcare systems. We are now facing a true challenge – how to boost the pharmaceutical sector’s global competitiveness and create a regulatory environment, which is attractive for innovation and investment in an economically sustainable way?

The calm before the storm? – Finnish merger control enforcement in 2021

D&I’s annual merger control report highlights the most recent trends and developments in Finnish merger control enforcement. In many ways, the year 2021 was not as exceptional as the preceding few years of Finnish merger control enforcement. For example, there were no proposals by the Finnish Competition and Consumer Authority (the “FCCA”) to prohibit a concentration (there was one in 2019 and one in 2020). Also, the FCCA did not declare a single notification incomplete or use ‘stop-the-clocks’. However, this does not mean that the Finnish merger control enforcement would have eased off. On the contrary, for example, the FCCA started to require an upfront buyer in divestment remedies and made significant new legislative proposals to tighten the merger control rules, which might mean that the year 2021 was merely a calm before the storm.

New winds in the healthtech regulatory sector

As the year 2021 is drawing to a close and the new year is just around the corner, it is time to take a look at what the ongoing year has brought regulation-wise to the health technology sector and what is yet to come during the following year. What does the existing and upcoming legislation mean for health technology in Finland? How can we use legislation as a tool to improve the innovation ecosystem in this sector? We interviewed regulatory expert Sandra Liede from Healthtech Finland.

Latest insights

First large-scale climate litigation filed in Finland

Alert / 29 Nov 2022
Reading time 3 minutes

The Power of Collaboration – The best things happen when smart people work together

Article / 31 Oct 2022
Reading time 2 minutes